Northwell Health
The purpose of this research study is to determine the safety and feasibility of using the UroNav software and DynaCAD software for planning and treating prostate cancer as an add on to the already approved workflow of using ultrasound only during the cryoablation of the prostate. The software application may aid doctors in locating a prior biopsy proven cancer location from the UroNav biopsy that patients previously had and then use that information to guide the treatment.
This is a single-center, prospective, single arm study to evaluate feasibility of UroNAV Ablation system aided cryo-ablation treatment of low and intermediate risk, organ-confined prostate cancer. All subjects will be treated and then followed up clinically for up to 24 months to evaluate any procedure or device related adverse events as well as to assess efficacy endpoints of the study. Additional data related to quality of life of treated subjects will also be collected
Inclusion Criteria: 1. Patients must have documented histological or cytological evidence of tumor(s) of the prostate. Patients requiring salvage cryotherapy for recurrent disease after primary radiation therapy of the prostate. 2. Patients must be ≥ 45 years of age. 3. Patients must be able to read, understand and sign an informed consent. 4. Primary Focal Therapy: Organ confined clinical T1C or clinical T2a prostate cancer that is visualized on MR imaging. Salvage post radiation focal therapy can include patients with local progression with SVI or EPE if it is within the treatment plan. 5.…
Focal ultrasound guided cryoablation using uroNav system Version 4.0 and Dyna CAD software version 5.0.